Manuel Mendizabal

Manuel Mendizabal

Auto-generated profile, based on publicly available information

Manuel Mendizabal

Unidad de Hígado y Trasplante Hepático, Hospital Universitario Austral, Pilar, Argentina

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Journal of Hepatology
Verified
Journal Article
Closed access
JAJuan Pablo Arab
Juan Pablo Arab
LDLuis Antonio Díaz
Luis Antonio Díaz
NBNatalia Baeza
Natalia Baeza
FIFrancisco Idalsoaga
Francisco Idalsoaga
EFEduardo Fuentes-López
Eduardo Fuentes-López
RBRamon Bataller
Ramon Bataller

23 June 2022 in Hepatology
Verified
Journal Article
Closed access
CECumali Efe
Cumali Efe
AKAnand V Kulkarni
Anand V Kulkarni
BBBenedetta Terziroli Beretta‐Piccoli
Benedetta Terziroli Beretta‐Piccoli
BMBianca Magro
Bianca Magro
ASAlbert Stättermayer
Albert Stättermayer
SWStaffan Wahlin
Staffan Wahlin

13 December 2010 in Liver Transplantation
Verified
Journal Article
Open access
PDF file
MMManuel Mendizabal
Manuel Mendizabal
RRRajender K. Reddy
Rajender K. Reddy
JCJames Cassuto
James Cassuto
KOKim M. Olthoff
Kim M. Olthoff
TFThomas W. Faust
Thomas W. Faust
PAPeter L. Abt
Peter L. Abt
The improved life expectancy of patients with cystic fibrosis (CF) has led to a change in the impact of liver disease on the prognosis of this population. Liver transplantation has emerged as the procedure of choice for patients with CF and features of hepatic decompensation and for intractable variceal bleeding as a major manifestation. We retrospectively reviewed the United Network for Organ Sharing database to analyze the outcomes of 55 adults and 148 children with CF who underwent liver transplantation, and we compared them to patients who underwent transplantation for other etiologies. We additionally compared the benefits of liver transplantation among patients who underwent transplantation for cystic fibrosis-related liver disease (CFLD) and those who remained on the waiting list. The 5-year survival rates for children and adults undergoing liver transplantation were 85.8% and 72.7%, respectively (P = 0.016). A multivariate Cox regression analysis comparing pediatric and adult CF patients to patients who underwent transplantation for other etiologies noted lower 5-year survival rates (P < 0.0001). However, compared to those remaining on the waiting list, pediatric transplant recipients with CF (hazard ratio = 0.33, 95% confidence interval = 0.16-0.70, P = 0.004) and adult transplant recipients with CF (hazard ratio = 0.25, 95% confidence interval = 0.11-0.57, P = 0.001) gained a significant survival benefit. In conclusion, long-term outcomes in patients with CFLD are acceptable but are inferior in comparison with the outcomes of those undergoing transplantation for other etiologies. Despite such observations, a survival benefit was noted in transplant patients versus those who remained on the waiting list. Liver Transpl, 2011. © 2011 AASLD.

1 January 2016 in World Journal of Gastroenterology
Verified
Journal Article
Open access
MMManuel Mendizabal
Manuel Mendizabal
MSMarcelo Oscar Silva
Marcelo Oscar Silva
Acute liver failure is a critical medical condition defined as rapid development of hepatic dysfunction associated with encephalopathy. The prognosis in these patients is highly variable and depends on the etiology, interval between jaundice and encephalopathy, age, and the degree of coagulopathy. Determining the prognosis for this population is vital. Unfortunately, prognostic models with both high sensitivity and specificity for prediction of death have not been developed. Liver transplantation has dramatically improved survival in patients with acute liver failure. Still, 25% to 45% of patients will survive with medical treatment. The identification of patients who will eventually require liver transplantation should be carefully addressed through the combination of current prognostic models and continuous medical assessment. The concerns of inaccurate selection for transplantation are significant, exposing the recipient to a complex surgery and lifelong immunosuppression. In this challenging scenario, where organ shortage remains one of the main problems, alternatives to conventional orthotopic liver transplantation, such as living-donor liver transplantation, auxiliary liver transplant, and ABO-incompatible grafts, should be explored. Although overall outcomes after liver transplantation for acute liver failure are improving, they are not yet comparable to elective transplantation.

1 May 2019 in Annals of Hepatology
Verified
Journal Article
Open access
FPFederico Piñero
Federico Piñero
MVMartín Vazquez
Martín Vazquez
PBPatricia Bare
Patricia Bare
CRCristian Rohr
Cristian Rohr
MMManuel Mendizabal
Manuel Mendizabal
MSMarcelo Silva
Marcelo Silva
A pro-oncogenic intestinal microbiome was observed in murine models; however, no specific microbiome in patients with hepatocellular carcinoma (HCC) has been reported. We aimed to compare the gut microbiome found in cirrhotic patients with or without HCC. From 407 patients with Child Pugh A/B cirrhosis prospectively followed, 25 with HCC (cases) were matched with 25 without HCC (wo-HCC) in a 1:1 ratio according to age, gender, etiology, Child Pugh and severity of portal hypertension. In addition, results were also compared with 25 healthy subjects. Fecal stool samples were sequenced for the V3-V4 region of the microbial 16S rRNA (Illumina MiSeq Platform). Plasma cytokines were quantified including interleukin-6 (IL-6) and tumor necrosis factor α (TNF-α). We found a differential abundance in family members of Firmicutes with a 3-fold increase of Erysipelotrichaceae and a 5-fold decrease in family Leuconostocaceae in HCC when compared to wo-HCC controls. Genus Fusobacterium was found to be 5-fold decreased in HCC vs wo-HCC. The ratio bacteriodes/prevotella was increased in HCC. Three operational taxonomic units (OTUs), genus Odoribacter and Butyricimonas were more abundant in HCC, whereas a decreased abundance in Lachnospiraceae family genus Dorea was observed in HCC patients. A Random Forest model trained with differential abundant taxa correctly classified HCC individuals. This pattern was associated with an inflammatory milieu with a putative increased activation of NOD-like receptor pathways. We found a pattern of microbiome linked to inflammation that could be potentially useful as HCC biomarker after follow-up validation studies.

16 June 2021 in Hepatology
Verified
Journal Article
Closed access
PDF file
LDLuis Antonio Díaz
Luis Antonio Díaz
FIFrancisco Idalsoaga
Francisco Idalsoaga
EFEduardo Fuentes-Lopez
Eduardo Fuentes-Lopez
AMAndrea Márquez‐Lomas
Andrea Márquez‐Lomas
CRCarolina A. Ramírez
Carolina A. Ramírez
JAJuan Pablo Arab
Juan Pablo Arab